本望　修 (ホンモウ　オサム)

写真a

所属

附属再生医学研究所 神経再生医療学部門

職名

教授
このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 　
    -
    1989年

    札幌医科大学  

  • 　
    -
    1989年

    札幌医科大学  

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 博士（医学）

このページの先頭へ▲

所属学協会 【 表示 ／ 非表示 】

  • 　
    　
    　

    神経の成長

  • 　
    　
    　

    脳循環代謝学会

  • 　
    　
    　

    日本脳卒中学会

  • 　
    　
    　

    日本分子脳神経外科研究会

  • 　
    　
    　

    Society for Neuroscience (USA)

全件表示 >>

このページの先頭へ▲

researchmapの所属 【 表示 ／ 非表示 】

  • 札幌医科大学   医学部 医学科 脳神経外科学講座 医学部医学科臨床医学部門講座脳神経外科学講座   講師  

このページの先頭へ▲
 

研究キーワード 【 表示 ／ 非表示 】

  • 脳神経外科学

このページの先頭へ▲

Misc 【 表示 ／ 非表示 】

  • Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy

    H Hamada, M Kobune, K Nakamura, Y Kawano, K Kato, O Honmou, K Houkin, T Matsunaga, YN Niitsu

    CANCER SCIENCE ( BLACKWELL PUBLISHING INC )  96 ( 3 ) 149 - 156  2005年03月

    書評論文，書評，文献紹介等  

    　概要を見る

    We developed human mesenchymal stem cell (MSC) lines that could differentiate into various tissue cells including bone, neural cells, bone marrow (BM) stromal cells supporting the growth of hematopoietic stem cell (HSC), and so-called 'tumor stromal cells' mixing with tumor cells. We investigated the applicability of MSC as therapeutic cell transplanting reagents (cytoreagents). Telomerized human BM derived stromal cells exhibited a prolonged lifespan and supported the growth of hematopoietic clonogenic cells. The gene transfer of Indian hedgehog (Ihh) remarkably enhanced the HSC expansion supported by the human BM stromal cells. Gene-modified MSC are useful as therapeutic tools for brain tissue damage (e.g. brain infarction) and malignant brain neoplasms. MSC transplantation protected the brain tissue from acute ischemic damage in the midcerebral artery occlusion (MCAO) animal model. Brain-derived neurotrophic factor (BDNF)-gene transduction further enhanced the protective efficacy against the ischemic damage. MSC possessed excellent migratory ability and exerted inhibitory effects on the proliferation of glioma cells. Gene-modification of MSC with therapeutic cytokines clearly augmented the antitumor effect and prolonged the survival of tumor-bearing animals. Gene therapy employing MSC as a tissue-protecting and targeting cytoreagent would be a promising approach.

    DOI PubMed

  • Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model

    K Kurozumi, K Nakamura, T Tamiya, Y Kawano, K Ishii, M Kobune, S Hirai, H Uchida, K Sasaki, Y Ito, K Kato, O Honmou, K Houkin, Date, I, H Hamada

    MOLECULAR THERAPY ( ACADEMIC PRESS INC ELSEVIER SCIENCE )  11 ( 1 ) 96 - 104  2005年01月

    　概要を見る

    Mesenchymal stem cells (MSC) were reported to ameliorate functional deficits after stroke in rats, with some of this improvement possibly resulting from the action of cytokines secreted by these cells. To enhance such cytokine effects, we previously transfected the telomerized human MSC with the BDNF gene using a fiber-mutant adenovirus vector and reported that such treatment contributed to improved ischemic recovery in a rat transient middle cerebral artery occlusion (MCAO) model. In the present study, we investigated whether other cytokines in addition to BDNF, i.e., GDNF, CNTF, or NT3, might have a similar or greater effect in this model. Rats that received MSC-BDNF (P < 0.05) or MSC-GDNF (P < 0.05) showed significantly more functional recovery as demonstrated by improved behavioral test results and reduced ischemic damage on MRI than did control rats 7 and 14 days following MCAO. On the other hand, rats that received MSC-CNTF or MSC-NT3 showed neither functional recovery nor ischemic damage reduction compared to control rats. Thus, MSC transfected with the BDNF or GDNF gene resulted in improved function and reduced ischemic damage in a rat model of MCAO. These data suggest that gene-modified cell therapy may be a useful approach for the treatment of stroke.

    DOI

  • Autologous transplantation of expanded neural precursor cells into the demyelinated monkey spinal cord

    S Oka, O Honmou, Y Akiyama, M Sasaki, K Houkin, K Hashi, JD Kocsis

    BRAIN RESEARCH ( ELSEVIER SCIENCE BV )  1030 ( 1 ) 94 - 102  2004年12月

    　概要を見る

    The objective of this study was to establish if neural precursor cells could safely be developed from biopsy of the subventricular zone (SVZ) in the non-human primate (marmoset), and to determine their myelinating potential after autologous transplantation into a demyelinated lesion. Small amounts of tissue were safely collected from the subventricular-subependymal zone of the adult primate brain under ultrasonography without any neurological deficit. Neural precursor cells were isolated and expanded in the presence of mitogen in vitro. The dorsal columns of the adult marmoset spinal cord were demyelinated by X-irradiation and intraspinal injections of ethidium bromide in the center of the radiation field. Cell suspensions of the neural precursors were microinjected through a micropipette into the demyelinated lesion site in the spinal cord. Lesions were histologically examined 3 weeks after transplantation. Light and electron microscopic examination of plastic embedded sections revealed a significant number of myelinating profiles in the transplantation zone; no myelination was observed in control lesions. The myelinated axons had predominantly peripheral patterns of myelination. These results demonstrate that autologous transplantation of neural precursor cells in the adult nonhuman primate can remyelinate demyelinated central nervous system (CNS) axons, thus suggesting the potential utility of such an approach in demyelinating lesions in humans. (C) 2004 Elsevier B.V. All rights reserved.

    DOI

  • Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model

    K Nakamura, Y Ito, Y Kawano, K Kurozumi, M Kobune, H Tsuda, A Bizen, O Honmou, Y Niitsu, H Hamada

    GENE THERAPY ( NATURE PUBLISHING GROUP )  11 ( 14 ) 1155 - 1164  2004年07月

    　概要を見る

    The prognosis of patients with malignant glioma is extremely poor, despite the extensive surgical treatment that they receive and recent improvements in adjuvant radio- and chemotherapy. In the present study, we propose the use of gene-modified mesenchymal stem cells (MSCs) as a new tool for gene therapy of malignant brain neoplasms. Primary MSCs isolated from Fischer 344 rats possessed excellent migratory ability and exerted inhibitory effects on the proliferation of 9L glioma cell in vitro. We also confirmed the migratory capacity of MSCs in vivo and showed that when they were inoculated into the contralateral hemisphere, they migrated towards 9L glioma cells through the corpus callosum. MSCs implanted directly into the tumor localized mainly at the border between the 9L tumor cells and normal brain parenchyma, and also infiltrated into the tumor bed. Intratumoral injection of MSCs caused significant inhibition of 9L tumor growth and increased the survival of 9L glioma-bearing rats. Gene-modification of MSCs by infection with an adenoviral vector encoding human interleukin-2 (IL-2) clearly augmented the antitumor effect and further prolonged the survival of tumor-bearing rats. Thus, gene therapy employing MSCs as a targeting vehicle would be promising as a new therapeutic approach for refractory brain tumor.

    DOI

  • A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats

    S Iihoshi, O Honmou, K Houkin, K Hashi, JD Kocsis

    BRAIN RESEARCH ( ELSEVIER SCIENCE BV )  1007 ( 1-2 ) 1 - 9  2004年05月

    　概要を見る

    The primary objective of this study was to test the hypothesis that intravenous administration of autologous bone marrow cells could improve functional recovery after middle cerebral artery occlusion (MCAO) for 45 min in the rat and to determine specific time windows for efficacy. Mononuclear cells from autologous bone marrow were transfected with the LacZ reporter gene, and injected intravenously into rats at 3-72 h after induction of MCAO. Histological analysis of the ischemic lesion at 14 days after transplantation revealed reduced ischemic lesion volume. Lesion volume was 250 +/- 45 mm(3) (n = 6) after MCAO without cell transplantation. Lesions were minimally detected by absence of 2,3,5-triphenyltetrazolium chloride (TTC) staining when bone marrow cells were infused 3 h after lesion induction. Lesions were clearly detected beginning with the 6-h postlesion group and became progressively larger at 12, 24 and 72 h (80 +/- 25, 140 +/- 18, and 180 +/- 22 mm(3), respectively; n=6 for each group). Transplanted LacZ(+) bone marrow cells accumulated extensively in and around the ischemic lesions, and immunohistochemistry suggests some neuronal and glial lineage differentiation. Behavioral testing (Morris water maze and Treadmill stress test) indicated greater functional recovery in the treated group. These findings suggest that early intervention with intravenous administration of autologous mononuclear cells from bone marrow can reduce lesion size in the MCAO model in the rat, and improve functional outcome. (C) 2004 Elsevier B.V. All rights reserved.

    DOI

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 日本再生医療学会 感謝状

    2002年  

  • 日本分子脳神経外科研究会 感謝状

    2001年  

  • 日本脳神経外科コングレス 感謝状

    2000年  

  • 日本分子脳神経外科研究会 感謝状

    2000年  

このページの先頭へ▲

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

  • 神経幹細胞

  • 神経移植

  • 遺伝子療法

  • 神経再生

このページの先頭へ▲